Search for Clinical Trial Results

Sponsored By

Hemangioblastoma - 4 Studies Found

Status Study
Terminated Study Name: Evaluation of Sunitinib Malate in Patients With Von Hippel-Lindau Syndrome (VHL) Who Have VHL Lesions to Follow
Condition:
  • Von Hippel-Lindau Syndrome
  • Renal Cell Carcinoma
  • Date: 2006-05-26
    Interventions: Drug: SU011248 50 mg/day orally for 4 weeks, no treatment for 2 weeks (6 weeks = 1 cycle).
Completed Study Name: Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma
Condition:
  • CNS Cancer
  • Meningioma
  • Intracranial Hemangiopericytoma

    • Date: 2007-12-26
    Interventions: Drug: Sunitinib The study drug will be administered on an outpatient basis. The starting dose will be 50
Completed Study Name: Visualizing Vascular Endothelial Growth Factor (VEGF) Producing Lesions in Von Hippel-Lindau Disease
Condition:
  • Von Hippel-Lindau Disease
  • Hemangioblastoma
  • Deafness
  • Kidney Diseases
  • Kidney Neoplasms